Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.

Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunother. 2009 Jan;32(1):12-21. doi: 10.1097/CJI.0b013e318189f13c.

2.

Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.

Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC.

J Immunother. 2006 Jul-Aug;29(4):416-24.

PMID:
16799337
3.

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM.

J Exp Med. 2003 Dec 15;198(12):1875-86.

4.

CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes.

Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA.

Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10878-83. Epub 2003 Aug 29.

5.

Sub-optimal CD4+ T-cell activation triggers autonomous TGF-β-dependent conversion to Foxp3+ regulatory T cells.

Oliveira VG, Caridade M, Paiva RS, Demengeot J, Graca L.

Eur J Immunol. 2011 May;41(5):1249-55. doi: 10.1002/eji.201040896.

6.

Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway.

Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Filbey KJ, Finney CA, Greenwood EJ, Knox DP, Wilson MS, Belkaid Y, Rudensky AY, Maizels RM.

J Exp Med. 2010 Oct 25;207(11):2331-41. doi: 10.1084/jem.20101074. Epub 2010 Sep 27.

7.

TGF-β induces surface LAP expression on murine CD4 T cells independent of Foxp3 induction.

Oida T, Weiner HL.

PLoS One. 2010 Nov 24;5(11):e15523. doi: 10.1371/journal.pone.0015523.

8.

Aurintricarboxylic acid promotes the conversion of naive CD4+CD25- T cells into Foxp3-expressing regulatory T cells.

Lim DG, Park YH, Kim SE, Kim YH, Park CS, Kim SC, Park CG, Han DJ.

Int Immunol. 2011 Sep;23(9):583-92. doi: 10.1093/intimm/dxr058. Epub 2011 Jul 12.

PMID:
21750147
9.

Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.

Su H, Ye DQ, Wang BL, Fang XH, Chen J, Wang Q, Li WX, Zhang N.

Br J Dermatol. 2008 Jun;158(6):1197-209. doi: 10.1111/j.1365-2133.2008.08555.x. Epub 2008 Apr 10.

PMID:
18410422
10.

Generation of highly effective and stable murine alloreactive Treg cells by combined anti-CD4 mAb, TGF-β, and RA treatment.

Schliesser U, Chopra M, Beilhack A, Appelt C, Vogel S, Schumann J, Panov I, Vogt K, Schlickeiser S, Olek S, Wood K, Brandt C, Volk HD, Sawitzki B.

Eur J Immunol. 2013 Dec;43(12):3291-305. doi: 10.1002/eji.201243292. Epub 2013 Sep 9.

11.

Critical Role of TGF-β and IL-2 Receptor Signaling in Foxp3 Induction by an Inhibitor of DNA Methylation.

Freudenberg K, Lindner N, Dohnke S, Garbe AI, Schallenberg S, Kretschmer K.

Front Immunol. 2018 Feb 2;9:125. doi: 10.3389/fimmu.2018.00125. eCollection 2018.

12.

Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg.

Lu L, Ma J, Wang X, Wang J, Zhang F, Yu J, He G, Xu B, Brand DD, Horwitz DA, Shi W, Zheng SG.

Eur J Immunol. 2010 Jan;40(1):142-52. doi: 10.1002/eji.200939618.

13.

Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.

Kang N, Tang L, Li X, Wu D, Li W, Chen X, Cui L, Ba D, He W.

Immunol Lett. 2009 Aug 15;125(2):105-13. doi: 10.1016/j.imlet.2009.06.005. Epub 2009 Jun 17.

PMID:
19539651
14.

Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer.

Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P, Linehan DC.

J Immunol. 2010 Oct 1;185(7):4063-71. doi: 10.4049/jimmunol.0902609. Epub 2010 Aug 30.

15.

Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.

Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA.

J Immunol. 2009 Sep 15;183(6):3682-9. doi: 10.4049/jimmunol.0900560. Epub 2009 Aug 19.

16.

Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.

Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E.

Cancer Immunol Immunother. 2007 Jan;56(1):48-59. Epub 2006 Apr 13.

PMID:
16612596
17.

"Default" generation of neonatal regulatory T cells.

Wang G, Miyahara Y, Guo Z, Khattar M, Stepkowski SM, Chen W.

J Immunol. 2010 Jul 1;185(1):71-8. doi: 10.4049/jimmunol.0903806. Epub 2010 May 24.

18.

Transforming growth factor-beta and all-trans retinoic acid generate ex vivo transgenic regulatory T cells with intestinal homing receptors.

Moore C, Sauma D, Morales J, Bono MR, Rosemblatt M, Fierro JA.

Transplant Proc. 2009 Jul-Aug;41(6):2670-2. doi: 10.1016/j.transproceed.2009.06.130.

PMID:
19715998
19.

C6-ceramide in combination with transforming growth factor-β enhances Treg cell differentiation and stable FoxP3 expression in vitro and in vivo.

Kue CS, Lim HX, Jung MY, Hong HJ, Cho D, Kim TS.

Immunobiology. 2013 Jul;218(7):952-9. doi: 10.1016/j.imbio.2012.11.003. Epub 2012 Nov 21.

PMID:
23313049
20.

CD103 is a hallmark of tumor-infiltrating regulatory T cells.

Anz D, Mueller W, Golic M, Kunz WG, Rapp M, Koelzer VH, Ellermeier J, Ellwart JW, Schnurr M, Bourquin C, Endres S.

Int J Cancer. 2011 Nov 15;129(10):2417-26. doi: 10.1002/ijc.25902. Epub 2011 Apr 1.

Supplemental Content

Support Center